APACHE: An open label, randomized, phase 2 study of the anti-programmed death-ligand 1 (PD-L1) durvalumab (D, MEDI4736), alone or in combination with tremelimumab (T), in patients (pts) with advanced germ cell tumors (GCT)

被引：0
|
作者：
Necchi, A. [1 ]
Mariani, L. [2 ]
Anichini, A. [3 ]
Giannatempo, P. [1 ]
Raggi, D. [1 ]
Togliardi, E. [4 ]
Calareso, G. [5 ]
Di Genova, N. [1 ]
Crippa, F. [6 ]
Salvioni, R. [7 ]
机构：
[1] Fdn IRCCS Ist Nazl Tumori, Med Oncol, Milan, Italy
[2] Fdn IRCCS Ist Nazl Tumori, Clin Epidemiol & Trials Org Unit, Milan, Italy
[3] Fdn IRCCS Ist Nazl Tumori, Expt Oncol & Mol Med, Milan, Italy
[4] Fdn IRCCS Ist Nazl Tumori, Pharm Unit, Milan, Italy
[5] Fdn IRCCS Ist Nazl Tumori, Radiol, Milan, Italy
[6] Fdn IRCCS Ist Nazl Tumori, Nucl Med & PET Unit, Milan, Italy
[7] Fdn IRCCS Ist Nazl Tumori, Surg Oncol, Milan, Italy
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw373.73
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
846TiP
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase I, open-label study of MEDI0680, an anti-programmed cell death-1 (PD-1) antibody, in combination with MEDI4736, an anti-programmed cell death ligand-1 (PD-L1) antibody, in patients with advanced malignancies.
    Hamid, Omid
    Chow, Laura Quan Man
    Tavakkoli, Fatemeh
    Marshall, Shannon
    Gribbin, Matthew Joseph
    Karakunnel, Joyson Joseph
    Gray, Jhanelle Elaine
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [2] A phase I study to evaluate the safety and tolerability of MEDI4736, an anti- programmed cell death-ligand-1 (PD-L1) antibody, in combination with tremelimumab in patients with advanced solid tumors.
    Ott, Patrick Alexander
    Callahan, Margaret K.
    Odunsi, Kunle
    Park, Andrew J.
    Pan, Linda S.
    Venhaus, Ralph Rudolph
    Karakunnel, Joyson Joseph
    Hodi, F. Stephen
    Wolchok, Jedd D.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [3] Population pharmacokinetics of MEDI4736, a fully human anti-programmed death ligand 1 (PD-L1) monoclonal antibody, in patients with advanced solid tumors
    Song, X.
    Pak, M.
    Chavez, C.
    Liang, M.
    Lu, H.
    Blake-Haskins, J. A.
    Robbins, P. B.
    Jin, X.
    Gupta, A.
    Roskos, L.
    Narwal, R.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S28 - S28
  • [4] Apache: An open label, randomized, phase 2 study of durvalumab (Durva), alone or in combination with tremelimumab (Treme), in patients (pts) with advanced germ cell tumors (GCT): Results at the end of first stage
    Raggi, Daniele
    Giannatempo, Patrizia
    Mariani, Luigi
    Colecchia, Maurizio
    Calareso, Giuseppina
    Salvioni, Roberto
    Ali, Siraj Mahamed
    Ross, Jeffrey S.
    Chung, Jon
    Necchi, Andrea
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [5] Phase I study to evaluate the safety and tolerability of MEDI4736, an anti-programmed cell death ligand-1 (PD-L1) antibody, in Japanese patients with advanced solid tumors.
    Iguchi, Haruo
    Nogami, Naoyuki
    Kozuki, Toshiyuki
    Matsumoto, Toshihiko
    Tamura, Kenji
    Yamamoto, Noboru
    Shimomura, Akihiko
    Hoshino, Yuji
    Michibata, Yoshiko
    Nii, Masahiro
    Fujiwara, Yutaka
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [6] Pharmacokinetics and pharmacodynamics of MEDI4736, a fully human anti-programmed death ligand 1 (PD-L1) monoclonal antibody, in patients with advanced solid tumors.
    Song, Xuyang
    Pak, Min
    Chavez, Carlos
    Liang, Meina
    Lu, Hong
    Schwickart, Martin
    Blake-Haskins, John A.
    Robbins, Paul B.
    Jin, Xiaoping
    Gupta, Ashok Kumar
    Roskos, Lorin
    Narwal, Rajesh
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [7] APACHE: An open label, randomized, phase II study of Durvalumab (Durva), alone or in combination with Tremelimumab (Treme), in patients (pts) with advanced germ cell tumors (GCT): Results at the end of first stage
    Necchi, Andrea
    Mariani, Luigi
    Raggi, Daniele
    Giannatempo, Patrizia
    Colecchia, Maurizio
    Calareso, Giuseppina
    Salvioni, Roberto
    Ali, Siraj M.
    Chung, Jon H.
    CANCER RESEARCH, 2018, 78 (13)
  • [8] Pharmacokinetics and pharmacodynamics of MEDI4736, a fully human anti-programmed death ligand 1 (PD-L1) monoclonal antibody, in combination with tremelimumab in patients with advanced non-small cell lung cancer (NSCLC).
    Tatipalli, Manasa
    Song, Xuyang
    Pak, Min
    Chavez, Carlos
    Liang, Meina
    Lu, Hong
    Schwickart, Martin
    Karakunnel, Joyson Joseph
    Robbins, Paul B.
    Jin, Xiaoping
    Gupta, Ashok Kumar
    Roskos, Lorin
    Narwal, Rajesh
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [9] Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC).
    Rizvi, Naiyer A.
    Brahmer, Julie R.
    Ou, Sai-Hong Ignatius
    Segal, Neil Howard
    Khleif, Samir
    Hwu, Wen-Jen
    Gutierrez, Martin
    Schoffski, Patrick
    Hamid, Omid
    Weiss, Jared
    Lutzky, Jose
    Maio, Michele
    Nemunaitis, John J.
    Jaeger, Dirk
    Balmanoukian, Ani Sarkis
    Rebelatto, Marlon
    Steele, Keith
    Li, Xia
    Blake-Haskins, John A.
    Antonia, Scott Joseph
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [10] A phase 1 study of MEDI4736, an anti PD-L1 antibody, in patients with advanced solid tumors.
    Lutzky, Jose
    Antonia, Scott Joseph
    Blake-Haskins, Andy
    Li, Xia
    Robbins, Paul B.
    Shaiabl, Aiman M.
    Vasseill, Jim
    Ibrahim, Ramy A.
    Khleif, Samir
    Segal, Neil Howard
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345